GT Medical Technologies has announced that 2,000 brain tumor patients have now been treated with its bioabsorbable collagen implant embedded with radiation seeds, GammaTile.
According to the Tempe, AZ-based company, the 2,000th patient was treated with the GammaTile implant at Jersey Shore University Medical Center in Neptune City, NJ.
GammaTile is designed for patients with operable brain tumors and is placed at the time of tumor removal surgery to deliver targeted radiation to the tumor site when cancer cells are at their lowest levels.
GammaTile received U.S. Food and Drug Administration (FDA) clearance in 2018 for recurrent brain tumors and in 2020 for newly diagnosed brain tumors.
Since its full market launch in March 2020, GammaTile has been adopted by more than 200 cancer centers, hospitals, and institutions in the U.S., GT Medical Technologies added.
